Peptide library
Bremelanotide: evidence profile
Approved product · Randomized evidence
Read each statement within its named product, route and evidence scope. The reading exercise below helps you examine a claim; it does not choose care.
Evidence record
- Product and route
- Subcutaneous injection.
- Approval scope
- Vyleesi: eligible premenopausal women with distressing acquired generalized low-desire disorder.
- Mechanism
- Melanocortin-receptor agonist.
- Evidence
- Randomized trials.
- Limits
- Exclude medical, relationship and drug causes; not performance enhancement.
- Safety context
- Uncontrolled hypertension or known cardiovascular disease: contraindicated.
A reading exercise
Take a comparative statement about bremelanotide and write its reference point in the margin. Is the comparison with an earlier measurement, another group or a defined reference value? Keep the measurement itself fixed and imagine changing only that reference point. Describe how the resulting question would change, without assigning a new numerical result. Return to the original passage and check that its conclusion uses the same comparison as its calculation. Before carrying the statement into a conversation, name both sides of the comparison. This gives the listener a way to understand what changed and what the comparison leaves untouched.
Questions to take away
- What exact reference point gives this comparison its meaning?
- How would the question change if the measurement stayed fixed but the reference changed?
- Does the conclusion retain the reference used in the calculation?
Sources
The dates below identify each source check. Publication of this page does not mean every source was checked again.